Product logins

Find logins to all Clarivate products below.


: Oncology

Here you will find relevant articles and insight into all Clarivate related products and news.

These six radioligand therapy companies to watch are ushering in a new era of precision oncology These six radioligand therapy companies to watch are ushering in a new era of precision oncology
Blog June 18, 2025
These six radioligand therapy companies to watch are ushering in a new era of precision oncology
Biopharma Clinical research Market Access
The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future
Blog June 21, 2024
The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future
Clinical research Clinical trials corporate
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Blog June 17, 2024
These seven ADC makers are developing therapies that show promise for hard-to-treat cancers
Clinical research Early drug development research Oncology
Indication Expansion: Pioneering new uses for existing cancer drugs Indication Expansion: Pioneering new uses for existing cancer drugs
Blog May 31, 2024
Indication Expansion: Pioneering new uses for existing cancer drugs
Clinical research Clinical trials Consulting Resource Center
Pharma is placing bigger bets on fewer, more strategic assets and platforms Pharma is placing bigger bets on fewer, more strategic assets and platforms
Blog May 8, 2024
Pharma is placing bigger bets on fewer, more strategic assets and platforms
Oncology Pharma Portfolio strategy
What sets the Drugs to Watch in 2024 apart What sets the Drugs to Watch in 2024 apart
Blog January 8, 2024
What sets the Drugs to Watch in 2024 apart
Clinical trials Mainland China Oncology
What to watch in the life sciences in 2024 What to watch in the life sciences in 2024
Blog December 14, 2023
What to watch in the life sciences in 2024
Oncology Pharma Portfolio strategy
Five points on CMS's first ten picks for price negotiations Five points on CMS's first ten picks for price negotiations
Blog October 25, 2023
Five points on CMS's first ten picks for price negotiations
Health policy Inflation Reduction Act IRA

Oncology

Blog October 31, 2019
Diverse approaches in immuno-oncology
Oncology, dermatology, hematology pace Q1 biopharma licensing Oncology, dermatology, hematology pace Q1 biopharma licensing
Blog June 11, 2019
Oncology, dermatology, hematology pace Q1 biopharma licensing
Blog April 18, 2019
Immuno-oncology spotlight on diverse therapeutic classes
Blog June 28, 2018
ASCO 2018: paradigm changers and emerging blockbusters
Blog June 25, 2018
Under ISP, How Will your Plan Assess an Oncology Drug’s Value for an Indication?
Blog April 25, 2018
ESMO session explores CDK inhibition and cell cycle modulation in cancer
Blog March 29, 2018
Oncology, driven by the promise of IO, dominates biopharma deals landscape
Blog January 23, 2018
As biopharma innovation accelerates, partnering follows suit
Blog November 14, 2017
Key steps forward in disease control in Sub-Saharan Africa
Blog October 11, 2017
Opioid Epidemic Spawns Flurry of PBM Programs to Address Abuse